Alaa El-Hussuna1, Aleksander Krag, Gunnar Olaison, Flemming Bendtsen, Lise L Gluud. 1. 1Department of Surgery, Slagelse Hospital, Slagelse, Denmark 2Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark 3Department of Surgery, Holbaek Hospital, University of Copenhagen, Copenhagen, Denmark 4Gastrounit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
Abstract
BACKGROUND: Patients with Crohn's disease treated with anti-tumor necrosis factor alpha agents may have an increased risk of surgical complications. OBJECTIVE: We assessed the effect of anti-tumor necrosis factor alpha on postoperative complications in patients with Crohn's disease undergoing abdominal surgery. DATA SOURCES: Studies were identified through electronic and manual searches. STUDY SELECTION: Observational studies on patients with Crohn's disease undergoing laparoscopic or open abdominal surgery were included. INTERVENTIONS: Anti-tumor necrosis factor alpha agents were administered within 3 months before surgery. MAIN OUTCOME MEASURES: The primary outcome was anastomotic complications including overt dehiscence, intra-abdominal abscess, and enteric fistulas. RESULTS: Fourteen studies on 679 patients in the intervention (anti-tumor necrosis factor alpha) group and 2363 controls were included. Random-effects meta-analysis found no difference in anastomotic complications between the 2 groups (7.6% versus 8.2%; risk ratio, 0.91; 95% CI, 0.56-1.48). There was clear heterogeneity between studies. In subgroup analyses, the anti-tumor necrosis factor alpha increased anastomotic complications in trials with a lower risk of bias, but not in the studies with a higher bias risk (risk ratio, 1.63; 95% CI, 1.03-2.60 and risk ratio, 0.17; 95% CI, 0.05-0.60). In the overall analysis and in studies with a lower bias risk, anti-tumor necrosis factor alpha agents increased the risk of nonanastomotic surgical complications, major medical complications, and minor medical complications. LIMITATIONS: Limitations of observations studies. CONCLUSIONS: In studies with a low risk of bias, anti-tumor necrosis factor alpha agents increased the risk of anastomotic complications. Inadequate bias control may lead to an underestimated risk of anastomotic complications.
BACKGROUND:Patients with Crohn's disease treated with anti-tumor necrosis factor alpha agents may have an increased risk of surgical complications. OBJECTIVE: We assessed the effect of anti-tumor necrosis factor alpha on postoperative complications in patients with Crohn's disease undergoing abdominal surgery. DATA SOURCES: Studies were identified through electronic and manual searches. STUDY SELECTION: Observational studies on patients with Crohn's disease undergoing laparoscopic or open abdominal surgery were included. INTERVENTIONS: Anti-tumor necrosis factor alpha agents were administered within 3 months before surgery. MAIN OUTCOME MEASURES: The primary outcome was anastomotic complications including overt dehiscence, intra-abdominal abscess, and enteric fistulas. RESULTS: Fourteen studies on 679 patients in the intervention (anti-tumor necrosis factor alpha) group and 2363 controls were included. Random-effects meta-analysis found no difference in anastomotic complications between the 2 groups (7.6% versus 8.2%; risk ratio, 0.91; 95% CI, 0.56-1.48). There was clear heterogeneity between studies. In subgroup analyses, the anti-tumor necrosis factor alpha increased anastomotic complications in trials with a lower risk of bias, but not in the studies with a higher bias risk (risk ratio, 1.63; 95% CI, 1.03-2.60 and risk ratio, 0.17; 95% CI, 0.05-0.60). In the overall analysis and in studies with a lower bias risk, anti-tumor necrosis factor alpha agents increased the risk of nonanastomotic surgical complications, major medical complications, and minor medical complications. LIMITATIONS: Limitations of observations studies. CONCLUSIONS: In studies with a low risk of bias, anti-tumor necrosis factor alpha agents increased the risk of anastomotic complications. Inadequate bias control may lead to an underestimated risk of anastomotic complications.
Authors: Martin Rehn; Peter-Martin Krarup; Lise H Christensen; Jakob B Seidelin; Magnus S Ågren; Ingvar Syk Journal: Surg Infect (Larchmt) Date: 2015-07-14 Impact factor: 2.150
Authors: Éanna J Ryan; Gabriel Orsi; Michael R Boland; Adeel Zafar Syed; Ben Creavin; Michael E Kelly; Kieran Sheahan; Paul C Neary; Dara O Kavanagh; Deirdre McNamara; Des C Winter; James M O'Riordan Journal: Int J Colorectal Dis Date: 2020-01-09 Impact factor: 2.571
Authors: Paulo Gustavo Kotze; Mansur Paulo Saab; Bárbara Saab; Lorete Maria da Silva Kotze; Marcia Olandoski; Lilian Vital Pinheiro; Carlos Augusto Real Martinez; Maria de Lourdes Setsuko Ayrizono; Daniela de Oliveira Magro; Claudio Saddy Rodrigues Coy Journal: Dig Dis Sci Date: 2016-12-08 Impact factor: 3.199
Authors: Yong Sik Yoon; Luca Stocchi; Stefan Holubar; Alexandra Aiello; Sherief Shawki; Emre Gorgun; Scott R Steele; Conor P Delaney; Tracy Hull Journal: Surg Endosc Date: 2020-05-28 Impact factor: 4.584
Authors: Cristina B Geltzeiler; Kyle D Hart; Kim C Lu; Karen E Deveney; Daniel O Herzig; Vassiliki L Tsikitis Journal: J Gastrointest Surg Date: 2015-08-19 Impact factor: 3.452
Authors: Afif N Kulaylat; Audrey S Kulaylat; Eric W Schaefer; Katelin Mirkin; Andrew Tinsley; Emmanuelle Williams; Walter A Koltun; Christopher S Hollenbeak; Evangelos Messaris Journal: J Gastrointest Surg Date: 2020-01-21 Impact factor: 3.452